Does the media prefer PEPG or FDMT?

In the previous week, 4D Molecular Therapeutics had 15 more articles in the media than PepGen. MarketBeat recorded 17 mentions for 4D Molecular Therapeutics and 2 mentions for PepGen. PepGen's average media sentiment score of 0.92 beat 4D Molecular Therapeutics' score of 0.53 indicating that PepGen is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment PepGen 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive 4D Molecular Therapeutics 7 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer RIGL or PEPG?

In the previous week, Rigel Pharmaceuticals had 10 more articles in the media than PepGen. MarketBeat recorded 12 mentions for Rigel Pharmaceuticals and 2 mentions for PepGen. Rigel Pharmaceuticals' average media sentiment score of 1.15 beat PepGen's score of 0.92 indicating that Rigel Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Rigel Pharmaceuticals 2 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive PepGen 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has better earnings & valuation, PEPG or PHAR?

Pharming Group has higher revenue and earnings than PepGen. PepGen is trading at a lower price-to-earnings ratio than Pharming Group, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio PepGen N/A N/A -$89.65M -$1.31 N/A Pharming Group $376.13M 2.23 $2.85M $0.12 98.75

Is PEPG or PHAR more profitable?

Pharming Group has a net margin of 2.51% compared to PepGen's net margin of 0.00%. Pharming Group's return on equity of 3.40% beat PepGen's return on equity. Company Net Margins Return on Equity Return on Assets PepGen N/A -51.01% -43.49% Pharming Group 2.51% 3.40% 1.90%

Which has higher earnings & valuation, PEPG or FTH?

PepGen is trading at a lower price-to-earnings ratio than Sensei Biotherapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio PepGen N/A N/A -$89.65M -$1.31 N/A Sensei Biotherapeutics N/A N/A -$21.08M -$141.65 N/A

Is PEPG or FTH more profitable?

PepGen's return on equity of -51.01% beat Sensei Biotherapeutics' return on equity. Company Net Margins Return on Equity Return on Assets PepGen N/A -51.01% -43.49% Sensei Biotherapeutics N/A -1,012.17% -175.69%

Does the media prefer PEPG or FTH?

In the previous week, Sensei Biotherapeutics had 3 more articles in the media than PepGen. MarketBeat recorded 5 mentions for Sensei Biotherapeutics and 2 mentions for PepGen. PepGen's average media sentiment score of 0.92 beat Sensei Biotherapeutics' score of 0.32 indicating that PepGen is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment PepGen 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Sensei Biotherapeutics 0 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has stronger earnings & valuation, PEPG or AURA?

Aura Biosciences is trading at a lower price-to-earnings ratio than PepGen, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio PepGen N/A N/A -$89.65M -$1.31 N/A Aura Biosciences N/A N/A -$106.19M -$1.75 N/A

Is PEPG or AURA more profitable?

PepGen's return on equity of -51.01% beat Aura Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets PepGen N/A -51.01% -43.49% Aura Biosciences N/A -73.18% -62.00%

Does the media prefer PEPG or AURA?

In the previous week, PepGen and PepGen both had 2 articles in the media. PepGen's average media sentiment score of 0.92 beat Aura Biosciences' score of 0.43 indicating that PepGen is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment PepGen 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Aura Biosciences 1 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

PepGen (PEPG) Competitors

$3.14 +0.10 (+3.29%)

As of 08/21/2026 04:00 PM Eastern

Compare

PEPG vs. FDMT, RIGL, PHAR, FTH, and AURA

Should you buy PepGen stock or one of its competitors? PepGen's main competitors and comparable companies include 4D Molecular Therapeutics (FDMT), Rigel Pharmaceuticals (RIGL), Pharming Group (PHAR), Sensei Biotherapeutics (FTH), and Aura Biosciences (AURA). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does PepGen compare to 4D Molecular Therapeutics?

PepGen (NASDAQ:PEPG) and 4D Molecular Therapeutics (NASDAQ:FDMT) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their earnings, dividends, risk, profitability, institutional ownership, valuation, analyst recommendations and media sentiment.

PepGen presently has a consensus target price of $11.50, suggesting a potential upside of 266.24%. 4D Molecular Therapeutics has a consensus target price of $29.63, suggesting a potential upside of 87.14%. Given PepGen's higher possible upside, analysts clearly believe PepGen is more favorable than 4D Molecular Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
PepGen	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71
4D Molecular Therapeutics	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.80

In the previous week, 4D Molecular Therapeutics had 15 more articles in the media than PepGen. MarketBeat recorded 17 mentions for 4D Molecular Therapeutics and 2 mentions for PepGen. PepGen's average media sentiment score of 0.92 beat 4D Molecular Therapeutics' score of 0.53 indicating that PepGen is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
PepGen	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
4D Molecular Therapeutics	7 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

58.0% of PepGen shares are owned by institutional investors. Comparatively, 99.3% of 4D Molecular Therapeutics shares are owned by institutional investors. 1.3% of PepGen shares are owned by company insiders. Comparatively, 7.9% of 4D Molecular Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

PepGen has a beta of 1.89, suggesting that its share price is 89% more volatile than the broader market. Comparatively, 4D Molecular Therapeutics has a beta of 2.73, suggesting that its share price is 173% more volatile than the broader market.

PepGen has a net margin of 0.00% compared to 4D Molecular Therapeutics' net margin of -194.74%. 4D Molecular Therapeutics' return on equity of -41.33% beat PepGen's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
PepGen	N/A	-51.01%	-43.49%
4D Molecular Therapeutics	-194.74%	-41.33%	-35.90%

PepGen has higher earnings, but lower revenue than 4D Molecular Therapeutics. 4D Molecular Therapeutics is trading at a lower price-to-earnings ratio than PepGen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
PepGen	N/A	N/A	-$89.65M	-$1.31	N/A
4D Molecular Therapeutics	$85.21M	10.26	-$140.11M	-$2.63	N/A

Summary

4D Molecular Therapeutics beats PepGen on 10 of the 16 factors compared between the two stocks.

How does PepGen compare to Rigel Pharmaceuticals?

Rigel Pharmaceuticals (NASDAQ:RIGL) and PepGen (NASDAQ:PEPG) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their media sentiment, dividends, earnings, analyst recommendations, profitability, institutional ownership, valuation and risk.

Rigel Pharmaceuticals has higher revenue and earnings than PepGen. PepGen is trading at a lower price-to-earnings ratio than Rigel Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Rigel Pharmaceuticals	$294.28M	2.88	$367.02M	$16.32	2.81
PepGen	N/A	N/A	-$89.65M	-$1.31	N/A

Rigel Pharmaceuticals has a beta of 1.16, meaning that its stock price is 16% more volatile than the broader market. Comparatively, PepGen has a beta of 1.89, meaning that its stock price is 89% more volatile than the broader market.

66.2% of Rigel Pharmaceuticals shares are held by institutional investors. Comparatively, 58.0% of PepGen shares are held by institutional investors. 10.5% of Rigel Pharmaceuticals shares are held by insiders. Comparatively, 1.3% of PepGen shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Rigel Pharmaceuticals has a net margin of 116.30% compared to PepGen's net margin of 0.00%. Rigel Pharmaceuticals' return on equity of 22.95% beat PepGen's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Rigel Pharmaceuticals	116.30%	22.95%	17.19%
PepGen	N/A	-51.01%	-43.49%

Rigel Pharmaceuticals presently has a consensus price target of $59.00, suggesting a potential upside of 28.57%. PepGen has a consensus price target of $11.50, suggesting a potential upside of 266.24%. Given PepGen's stronger consensus rating and higher possible upside, analysts clearly believe PepGen is more favorable than Rigel Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Rigel Pharmaceuticals	0 Sell rating(s)	3 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.57
PepGen	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71

In the previous week, Rigel Pharmaceuticals had 10 more articles in the media than PepGen. MarketBeat recorded 12 mentions for Rigel Pharmaceuticals and 2 mentions for PepGen. Rigel Pharmaceuticals' average media sentiment score of 1.15 beat PepGen's score of 0.92 indicating that Rigel Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Rigel Pharmaceuticals	2 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
PepGen	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Rigel Pharmaceuticals beats PepGen on 11 of the 15 factors compared between the two stocks.

How does PepGen compare to Pharming Group?

PepGen (NASDAQ:PEPG) and Pharming Group (NASDAQ:PHAR) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their media sentiment, valuation, dividends, profitability, risk, earnings, analyst recommendations and institutional ownership.

Pharming Group has a net margin of 2.51% compared to PepGen's net margin of 0.00%. Pharming Group's return on equity of 3.40% beat PepGen's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
PepGen	N/A	-51.01%	-43.49%
Pharming Group	2.51%	3.40%	1.90%

In the previous week, PepGen had 2 more articles in the media than Pharming Group. MarketBeat recorded 2 mentions for PepGen and 0 mentions for Pharming Group. Pharming Group's average media sentiment score of 1.93 beat PepGen's score of 0.92 indicating that Pharming Group is being referred to more favorably in the news media.

Company	Overall Sentiment
PepGen	Positive
Pharming Group	Very Positive

PepGen has a beta of 1.89, meaning that its share price is 89% more volatile than the broader market. Comparatively, Pharming Group has a beta of -0.01, meaning that its share price is 101% less volatile than the broader market.

Pharming Group has higher revenue and earnings than PepGen. PepGen is trading at a lower price-to-earnings ratio than Pharming Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
PepGen	N/A	N/A	-$89.65M	-$1.31	N/A
Pharming Group	$376.13M	2.23	$2.85M	$0.12	98.75

PepGen presently has a consensus price target of $11.50, suggesting a potential upside of 266.24%. Pharming Group has a consensus price target of $38.67, suggesting a potential upside of 226.30%. Given PepGen's stronger consensus rating and higher possible upside, equities research analysts plainly believe PepGen is more favorable than Pharming Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
PepGen	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71
Pharming Group	2 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.20

58.0% of PepGen shares are owned by institutional investors. Comparatively, 0.0% of Pharming Group shares are owned by institutional investors. 1.3% of PepGen shares are owned by insiders. Comparatively, 2.1% of Pharming Group shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Summary

Pharming Group beats PepGen on 9 of the 15 factors compared between the two stocks.

How does PepGen compare to Sensei Biotherapeutics?

PepGen (NASDAQ:PEPG) and Sensei Biotherapeutics (NASDAQ:FTH) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, risk, earnings, analyst recommendations, valuation, media sentiment, institutional ownership and profitability.

PepGen presently has a consensus price target of $11.50, suggesting a potential upside of 266.24%. Sensei Biotherapeutics has a consensus price target of $55.00, suggesting a potential upside of 71.88%. Given PepGen's higher probable upside, equities research analysts clearly believe PepGen is more favorable than Sensei Biotherapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
PepGen	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71
Sensei Biotherapeutics	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.85

58.0% of PepGen shares are held by institutional investors. Comparatively, 10.5% of Sensei Biotherapeutics shares are held by institutional investors. 1.3% of PepGen shares are held by insiders. Comparatively, 7.0% of Sensei Biotherapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

PepGen has a beta of 1.89, indicating that its share price is 89% more volatile than the broader market. Comparatively, Sensei Biotherapeutics has a beta of -0.25, indicating that its share price is 125% less volatile than the broader market.

PepGen is trading at a lower price-to-earnings ratio than Sensei Biotherapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
PepGen	N/A	N/A	-$89.65M	-$1.31	N/A
Sensei Biotherapeutics	N/A	N/A	-$21.08M	-$141.65	N/A

PepGen's return on equity of -51.01% beat Sensei Biotherapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
PepGen	N/A	-51.01%	-43.49%
Sensei Biotherapeutics	N/A	-1,012.17%	-175.69%

In the previous week, Sensei Biotherapeutics had 3 more articles in the media than PepGen. MarketBeat recorded 5 mentions for Sensei Biotherapeutics and 2 mentions for PepGen. PepGen's average media sentiment score of 0.92 beat Sensei Biotherapeutics' score of 0.32 indicating that PepGen is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
PepGen	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Sensei Biotherapeutics	0 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

PepGen and Sensei Biotherapeutics tied by winning 7 of the 14 factors compared between the two stocks.

How does PepGen compare to Aura Biosciences?

PepGen (NASDAQ:PEPG) and Aura Biosciences (NASDAQ:AURA) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their risk, analyst recommendations, media sentiment, earnings, profitability, institutional ownership, dividends and valuation.

Aura Biosciences is trading at a lower price-to-earnings ratio than PepGen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
PepGen	N/A	N/A	-$89.65M	-$1.31	N/A
Aura Biosciences	N/A	N/A	-$106.19M	-$1.75	N/A

PepGen's return on equity of -51.01% beat Aura Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
PepGen	N/A	-51.01%	-43.49%
Aura Biosciences	N/A	-73.18%	-62.00%

In the previous week, PepGen and PepGen both had 2 articles in the media. PepGen's average media sentiment score of 0.92 beat Aura Biosciences' score of 0.43 indicating that PepGen is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
PepGen	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Aura Biosciences	1 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

PepGen currently has a consensus price target of $11.50, indicating a potential upside of 266.24%. Aura Biosciences has a consensus price target of $17.50, indicating a potential upside of 124.36%. Given PepGen's stronger consensus rating and higher probable upside, research analysts clearly believe PepGen is more favorable than Aura Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
PepGen	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71
Aura Biosciences	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

58.0% of PepGen shares are owned by institutional investors. Comparatively, 96.8% of Aura Biosciences shares are owned by institutional investors. 1.3% of PepGen shares are owned by insiders. Comparatively, 1.9% of Aura Biosciences shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

PepGen has a beta of 1.89, indicating that its share price is 89% more volatile than the broader market. Comparatively, Aura Biosciences has a beta of 0.4, indicating that its share price is 60% less volatile than the broader market.

Summary

PepGen beats Aura Biosciences on 10 of the 12 factors compared between the two stocks.

Get PepGen News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PEPG and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

PEPG vs. The Competition

Export

Metric	PepGen	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$217.48M	$4.01B	$7.37B	$12.85B
Dividend Yield	N/A	3.64%	2.54%	11.08%
P/E Ratio	-2.40	11.62	272.88	24.24
Price / Sales	N/A	1,338.17	618.96	99.76
Price / Cash	N/A	105.14	78.62	53.99
Price / Book	1.82	16.80	13.05	6.20
Net Income	-$89.65M	-$12.50M	$3.47B	$348.59M
7 Day Performance	5.02%	3.29%	2.09%	0.08%
1 Month Performance	49.52%	8.23%	6.64%	3.88%
1 Year Performance	137.88%	55.05%	25.02%	16.98%

PepGen Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
PEPG PepGen	2.6067 of 5 stars	$3.14 +3.3%	$11.50 +266.2%	+137.9%	$217.48M	N/A	N/A	30
FDMT 4D Molecular Therapeutics	3.074 of 5 stars	$15.64 -2.9%	$29.63 +89.4%	+123.3%	$864.02M	$92.01M	N/A	120	Analyst Revision
RIGL Rigel Pharmaceuticals	4.567 of 5 stars	$45.82 +1.3%	$59.00 +28.8%	+10.6%	$847.76M	$276.79M	2.81	160	Positive News Analyst Revision
PHAR Pharming Group	3.9397 of 5 stars	$11.89 +1.8%	$38.67 +225.2%	-13.5%	$841.57M	$376.13M	99.08	280
FTH Sensei Biotherapeutics	4.3782 of 5 stars	$32.51 +1.3%	$55.00 +69.2%	N/A	$840.06M	N/A	N/A	40	News Coverage Analyst Forecast Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:PEPG) was last updated on 8/23/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

PepGen (PEPG) Competitors

PEPG vs. FDMT, RIGL, PHAR, FTH, and AURA

How does PepGen compare to 4D Molecular Therapeutics?

Summary

How does PepGen compare to Rigel Pharmaceuticals?

Summary

How does PepGen compare to Pharming Group?

Summary

How does PepGen compare to Sensei Biotherapeutics?

Summary

How does PepGen compare to Aura Biosciences?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PEPG vs. The Competition

PepGen Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

PepGen (PEPG) Competitors

PEPG vs. FDMT, RIGL, PHAR, FTH, and AURA

How does PepGen compare to 4D Molecular Therapeutics?

Do analysts prefer PEPG or FDMT?

Does the media prefer PEPG or FDMT?

Do institutionals and insiders hold more shares of PEPG or FDMT?

Which has more volatility & risk, PEPG or FDMT?

Is PEPG or FDMT more profitable?

Which has higher valuation and earnings, PEPG or FDMT?

Summary

How does PepGen compare to Rigel Pharmaceuticals?

Which has higher earnings and valuation, RIGL or PEPG?

Which has more volatility & risk, RIGL or PEPG?

Do institutionals & insiders hold more shares of RIGL or PEPG?

Is RIGL or PEPG more profitable?

Do analysts recommend RIGL or PEPG?

Does the media prefer RIGL or PEPG?

Summary

How does PepGen compare to Pharming Group?

Is PEPG or PHAR more profitable?

Does the media prefer PEPG or PHAR?

Which has more risk & volatility, PEPG or PHAR?

Which has better earnings & valuation, PEPG or PHAR?

Do analysts recommend PEPG or PHAR?

Do insiders and institutionals hold more shares of PEPG or PHAR?

Summary

How does PepGen compare to Sensei Biotherapeutics?

Do analysts rate PEPG or FTH?

Do institutionals and insiders have more ownership in PEPG or FTH?

Which has more volatility & risk, PEPG or FTH?

Which has higher earnings & valuation, PEPG or FTH?

Is PEPG or FTH more profitable?

Does the media prefer PEPG or FTH?

Summary

How does PepGen compare to Aura Biosciences?

Which has stronger earnings & valuation, PEPG or AURA?

Is PEPG or AURA more profitable?

Does the media prefer PEPG or AURA?

Do analysts recommend PEPG or AURA?

Do institutionals & insiders believe in PEPG or AURA?

Which has more volatility and risk, PEPG or AURA?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PEPG vs. The Competition

PepGen Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools